Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrae Vandross

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Journal of General Internal Medicine|June 23, 2012
Name-callingAndrae Vandross
Journal of Palliative Medicine|December 12, 2013
Who is my patient? Reflection of a trainee trying to play doctorAndrae Vandross
Seminars in Oncology|June 25, 2018
Proteasome inhibitor-based therapy for treatment of newly diagnosed multiple myelomaAndrae Vandross
Archives of Internal Medicine|June 12, 2013
Raise the bar even higher for primary prevention interventions-replyVinay Prasad, Andrae Vandross
Journal of Cancer Research and Clinical Oncology|January 30, 2014
Failing to improve overall survival because post-protocol survival is long: fact, myth, excuse or improper study design?Vinay Prasad, Andrae Vandross
Archives of Internal Medicine|April 25, 2012
Cardiovascular primary prevention: how high should we set the bar?Vinay Prasad, Andrae Vandross
Mayo Clinic Proceedings|November 8, 2015
Characteristics of Exceptional or Super Responders to Cancer DrugsVinay Prasad, Andrae Vandross
Seminars in Oncology|May 15, 2016
ASCO Plenary Sessions: impact, legacy, futureAndrae Vandross, Vinay Prasad, Sham Mailankody
JAMA Internal Medicine|June 23, 2015
The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analysesVinay Prasad, Chul Kim, Mauricio Burotto, et al.
Current Opinion in Nephrology and Hypertension|March 14, 2019
Atypical hemolytic uremic syndrome and complement blockade: established and emerging uses of complement inhibitionRamy M Hanna, Marina Barsoum, Andrae Vandross, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Journal of General Internal Medicine|June 23, 2012
Name-callingAndrae Vandross
Journal of Palliative Medicine|December 12, 2013
Who is my patient? Reflection of a trainee trying to play doctorAndrae Vandross
Seminars in Oncology|June 25, 2018
Proteasome inhibitor-based therapy for treatment of newly diagnosed multiple myelomaAndrae Vandross
Archives of Internal Medicine|June 12, 2013
Raise the bar even higher for primary prevention interventions-replyVinay Prasad, Andrae Vandross
Journal of Cancer Research and Clinical Oncology|January 30, 2014
Failing to improve overall survival because post-protocol survival is long: fact, myth, excuse or improper study design?Vinay Prasad, Andrae Vandross
Archives of Internal Medicine|April 25, 2012
Cardiovascular primary prevention: how high should we set the bar?Vinay Prasad, Andrae Vandross
Mayo Clinic Proceedings|November 8, 2015
Characteristics of Exceptional or Super Responders to Cancer DrugsVinay Prasad, Andrae Vandross
Seminars in Oncology|May 15, 2016
ASCO Plenary Sessions: impact, legacy, futureAndrae Vandross, Vinay Prasad, Sham Mailankody
JAMA Internal Medicine|June 23, 2015
The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analysesVinay Prasad, Chul Kim, Mauricio Burotto, et al.
Current Opinion in Nephrology and Hypertension|March 14, 2019
Atypical hemolytic uremic syndrome and complement blockade: established and emerging uses of complement inhibitionRamy M Hanna, Marina Barsoum, Andrae Vandross, et al.
Pageof 2